| | |
Item 1(a). | | Name of Issuer: |
| |
| | Rubius Therapeutics, Inc. (the “Issuer”) |
| |
Item 1(b). | | Address of Issuer’s Principal Executive Offices: |
| |
| | 399 Binney Street, Suite 300, Cambridge, Massachusetts 02139 |
| |
Item 2(a). | | Name of Person Filing: |
| |
Item 2(b). | | Address of Principal Business Office or, if none, Residence: |
| |
Item 2(c). | | Citizenship: |
| |
| | (i) Invus Public Equities, L.P. (“Invus Public Equities”) 750 Lexington Avenue, 30th Floor, New York, NY 10022 |
| | Citizenship: Bermuda limited partnership |
| |
| | (ii) Invus Public Equities Advisors, LLC (“Invus PE Advisors”) 750 Lexington Avenue, 30th Floor, New York, NY 10022 |
| | Citizenship: Delaware limited liability company |
| |
| | (iii) Artal Treasury Limited (“Artal Treasury”) |
| | Suite 4, Borough House, rue du Pré, St. Peter Port, Guernsey GY1 3JJ |
| | Citizenship: Guernsey company |
| |
| | (iv) Artal International S.C.A. (“Artal International”) |
| | Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg |
| | Citizenship: Luxembourg limited partnership |
| |
| | (v) Artal International Management S.A. (“Artal International Management”) |
| | Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg |
| | Citizenship: Luxembourg société anonyme |
| |
| | (vi) Artal Group S.A. (“Artal Group”) |
| | Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg |
| | Citizenship: Luxembourg société anonyme |
| |
| | (vii) Westend S.A. (“Westend”) |
| | Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg |
| | Citizenship: Luxembourg société anonyme |
| |
| | (viii) Stichting Administratiekantoor Westend (the “Stichting”) |
| | Claude Debussylaan, 46, 1082 MD Amsterdam, The Netherlands |
| | Citizenship: Netherlands foundation |
| |
| | (ix) Mr. Amaury Wittouck |
| | Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg |
| | Citizenship: Belgium |
| |
| | The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.” |
| |
Item 2(d). | | Title of Class of Securities: |
| |
| | Common Stock, par value $0.001 per share (the “Shares”) |